The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Ellington Residential Mortgaging Real Estate Investment Trust (EARN - Get Report) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.But making Ellington Residential Mortgaging Real Estate Investment Trust an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of EARN entered into oversold territory, changing hands as low as $12.67 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Ellington Residential Mortgaging Real Estate Investment Trust, the RSI reading has hit 27.6 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 46.4. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, EARN's recent annualized dividend of 2.20/share (currently paid in quarterly installments) works out to an annual yield of 15.80% based upon the recent $13.93 share price. A bullish investor could look at EARN's 27.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on EARN is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
More from Stocks
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
Could Netflix Survive on Just Its Own Original Content?
Netflix says that viewers shell out for original shows like Stranger Things and Orange is the New Black -- but production costs have ballooned roughly 30% since last year, which has many investors spooked.
Jim Cramer: Mastercard Is One Thing Money Can Buy
The slogan was: There are some things money can't buy; for everything else, there's Mastercard. Fast forward more than two decades and the world of fintech and digital payment processing has changed, and Mastercard has changed right along with it.